SEARCH

SEARCH BY CITATION

References

  • 1
    Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R., Sultan, C. (1976) Proposals for the classification of the acute leukaemias (FAB cooperative group). British Journal of Haematology, 33, 451 458.
  • 2
    Burnett, A.K., Goldstone, A.H., Stevens, R., Hann, I.M., Gray, R., Rees, J., Wheatley, K. (1996) Allo and auto BMT reduce relapse risk in AML in CR1 but do not significantly improve overall survival: results of the MRC AML 10 trial. British Journal of Haematology, 93, (Suppl. 2), 313 (A1184).
  • 3
    Burnett, A.K., Goldstone, A.H., Stevens, R.F., Hann, I.M., Rees, J.K.H., Gray, R.G., Wheatley, K. (1998) Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet, 351, 700 708.
  • 4
    Cheson, B.D., Cassileth, P.A., Head, D.R., Schiffer, C.A., Bennett, J.M., Bloomfield, C.D., Brunning, R., Gale, R.P., Grever, M.R., Keating, M.J. (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. Journal of Clinical Oncology, 8, 813 819.
  • 5
    Fenaux, P., Chomienne, C., Degos, L. (1997) Acute promyelocytic leukemia: biology and treatment. Seminars in Oncology, 24, 92 102.
  • 6
    Fenaux, P., Le Deley, M.C., Castaigne, S., Archimbaud, E., Chomienne, C., Link, H., Guerci, A., Duarte, M., Daniel, M.T., Bowen, D., Huebner, G., Bauters, F., Fegueux, N., Fey, M., Sanz, M., Lowenberg, B., Maloisel, F., Auzanneau, G., Sadoun, A., Gardin, C., Bastion, Y., Ganser, A., Jacky, E., Dombret, H., Chastang, C., Degos, L. (1993) Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood, 82, 3241 3249.
  • 7
    Goldstone, A.H., Burnett, A.K., Wheatley, K., Gray, R.G. (1996) Identification of good risk elderly patients with acute myeloid leukaemia (AML) who benefit from intensive therapy and extremely poor risk ones who do not: prognostic factor analysis of the MRC AML 11 trial. Blood, 88, (Suppl. 1), 291a (A1154).
  • 8
    Gray, R. & Wheatley, K. (1991) How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplantation, 7, (Suppl. 3), 9 12.
  • 9
    Grimwade, D., Howe, K., Langabeer, S., Davies, L., Oliver, F., Walker, H., Swirsky, D., Wheatley, K., Goldstone, A., Burnett, A., Solomon, E. (1996) Establishing the presence of the t(15:17) in suspected acute promyelocytic leukaemia: cytogenic, molecular and PML immunofluorescence assessment of patients entered into the MRC ATRA trial. British Journal of Haematology, 94, 557 573.
  • 10
    Grimwade, D., Walker, H., Wheatley, K., Oliver, F., Harrison, C., Harrison, G., Gray, R., Hann, I., Stevens, R., Rees, J., Burnett, A., Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood, 92, 2322 2333.
  • 11
    Hann, I.M., Stevens, R.F., Goldstone, A.H., Rees, J.K.H., Wheatley, K., Gray, R.G., Burnett, A.K. (1997) Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML 10). Blood, 89, 2311 2318.
  • 12
    Hart, S.M., Ganeshaguru, K., Hoffbrand, A.V., Prentice, H.G., Mehta, A.B. (1994) Expression of multi-drug resistance-associated protein (MRP) in acute leukemia. Leukemia, 8, 2163 2168.
  • 13
    Knapp, W., Strobl, H., Majidic, O. (1994) Flow cytometric analysis of cell surface and intracellular antigens in leukemia diagnosis. Cytometry, 18, 187 198.
  • 14
    Mertens, F., Johansson, B., Mitelman, F. (1993) Age- and gender-related heterogeneity of cancer chromosome aberrations. Cancer Genetics and Cytogenetics, 70, 6 11.
  • 15
    Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J., Smith, P.G. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II. Analysis and examples. British Journal of Cancer, 35, 1 39.
  • 16
    Tallman, M.S., Andersen, J.W., Schiffer, C.A., Appelbaum, F.R., Feusner, J.H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C.D., Rowe, J.M., Wiernik, P.H. (1997) All-trans-retinoic acid in acute promyelocytic leukemia . New England Journal of Medicine, 337, 1021 1028.
  • 17
    Watson, M., Wheatley, K., Burnett, A.K., Goldstone, A.H., Rees, J.K., Gray, R.G. (1996) The impact of allogeneic (Allo-BMT) and autologous (A-BMT) bone marrow transplant in first complete remission (CR1) on quality of life (QL) of patients with acute myeloid leukaemia (AML) entered into the MRC AML 10 trial. British Journal of Haematology, 93, (Suppl. 2), 146.
  • 18
    Wheatley, K., Burnett, A., Goldstone, A., Hann, I., Stevens, R., Rees, J., Gray, R. (1995) A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom Medical Research Council (MRC) AML 10 trial. Blood, 86, (Suppl. 1), 598a (A2381).
  • 19
    Wheatley, K., Burnett, A.K., Goldstone, A.H., Hann, I.M., Stevens, R.F., Rees, J.K.H., Gray, R.G. (1996) Factors relating to the achievement of complete remission (CR) in younger patients with acute myeloid leukaemia (AML) in the United Kingdom Medical Research Council (MRC) AML 10 trial. Blood, 88, (Suppl. 1), 214a (A8431).
  • 20
    Wood, P., Burgess, R., MacGregor, A., Yin, J.A. (1994) P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. British Journal of Haematology, 87, 509 514.
  • 21
    Zittoun, R., Suciu, S., Solbu, G., Watson, M., Muus, P., Mandelli, F., Stryckmans, P., Peetermans, M., Thaler, J., Resegotti, L., Dardenne, M., Willemze, R. (1997) Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplantation, 20, 307 315.